

Acromegaly therapy comparison*

Talk with your doctor to choose the therapy that's right for you

	long-acting lanreotide ^{1,2}	long-acting octreotide ³	short-acting octreotide ²⁻⁴	pegvisomant ^{5,6}
Lowers GH and IGF-1 levels	✓	✓	✓	
Injections per year	13	13 [†]	730 – 1,460	365
No daily injections required	✓	✓ [†]		
Ready to use, no mixing	✓		✓	
Prefilled syringe	✓			
Generally well tolerated	✓	✓	✓	✓
Injection volume	<0.5 mL	2.0 – 2.5 mL	1.0 mL	1.0 mL
Needle length	20 mm	40 mm	Variable	13 mm
Injection type	Deep subcutaneous	Deep intramuscular	Subcutaneous	Subcutaneous

*Comparative clinical significance is unknown. †Requires 2 weeks of daily injections as introductory therapy.

References: 1. Somatuline® Depot (lanreotide) Injection [prescribing information]. Paris, France: Beaufour Ipsen Pharma; 2007. 2. Data on file. Brisbane, CA: Tercica, Inc.; 2007. 3. Sandostatin LAR® Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006. 4. Sandostatin® Support Guide. Sandostatin® Web site. <http://www.us.sandostatin.com/pdf/SupportGuide.pdf>. Accessed January 3, 2008. 5. Somavert® [prescribing information]. New York, NY: Pfizer Inc; 2006. 6. Somavert® [patient information]. New York, NY: Pfizer Inc; 2006.

